191871-32-6

Basic information

• Product Name: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE
• Synonyms: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE;Benzeneacetic acid, 4-[[[(1,1-diMethylethoxy)carbonyl]aMino]Methyl]-, Methyl ester
• CAS NO: 191871-32-6
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33
• Mol File: 191871-32-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(191871-32-6)
• EPA Substance Registry System: TERT-BUTYL 4-((METHOXYCARBONYL)METHYL)BENZYLCARBAMATE(191871-32-6)

Safety Data

• Hazardous Substances Data: 191871-32-6(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 444807-46-9 2-(4-(aminomethyl)phenyl)acetic acid methyl ester 
• 52798-01-3 methyl 4-cyanobenzeneacetate 
• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 17833-56-6 ester monomethylique de l'acide p-phenylene diacetique 
• 4129-17-3 diphenylphosphoranyl azide 

Downstream Products

• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 
• 808753-20-0 2-(4-aminomethyl-phenyl)-N-methyl-N-(1-phenyl-2-pyrrolidin-1-yl-ethyl)-acetamide 
• 808753-17-5 [4-({methyl-[1-(S)-phenyl-2-pyrrolidin-1-yl-ethyl]-carbamoyl}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 99075-25-9 (4-aminomethylphenyl)-acetic acid methyl ester hydrochloride 

Relevant articles and documents

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Sulfonylamino phenylacetamide derivatives and methods of their use

Sulfonylamino phenylacetamide derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to κ opioid receptors; (2) display good opioid receptor selectivity of κ versus μ and κ versus δ; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.